Cervical Cancer: Expert advice on developing biomarker-based, patient-specific treatment plans | The Evolving Standard of Care: Immuno-Oncology Agents for Cervical Cancer | 0.5-hour CME/CE | #MedEd #cme #cervicalcancertreatment | https://bit.ly/4c0tXZA
PRIME Education’s Post
More Relevant Posts
-
Cervical Cancer: Expert advice on developing biomarker-based, patient-specific treatment plans | The Evolving Standard of Care: Immuno-Oncology Agents for Cervical Cancer | 0.5-hour CME/CE | #MedEd #cme #cervicalcancertreatment | https://bit.ly/4c0tXZA
-
-
Cervical Cancer: Expert advice on developing biomarker-based, patient-specific treatment plans | The Evolving Standard of Care: Immuno-Oncology Agents for Cervical Cancer | 0.5-hour CME/CE | #MedEd #cme #cervicalcancertreatment | https://bit.ly/4c0tXZA
-
-
This article from the Colon Cancer Foundation explains in more detail some of the risk factors and the process for screening: #salishcancercenter #cancercareforall #cancercareclosetohome #screening https://lnkd.in/g9Geagd2
-
This article from the Colon Cancer Foundation explains in more detail some of the risk factors and the process for screening: #salishcancercenter #cancercareforall #cancercareclosetohome #screening https://lnkd.in/g2DDbr3u
Prevent It - Colorectal Cancer Screening Information
https://coloncancerfoundation.org
-
A phase 1b study found the maximum tolerated dose to be 600 mg alectinib twice daily plus 40 mg cobimetinib daily for patients with ALK-positive lung cancer. Learn more: https://lnkd.in/eZAt8sKW
-
-
In a phase 3 trial, adding the novel PD-1 inhibitor toripalimab to standard chemotherapy significantly improved progression-free survival and overall survival in patients with extensive-stage small cell lung cancer. https://ja.ma/3URpIJb
-
-
Come check out how biology drives our cancer methylation signatures!
Adela is presenting at #aacrLBx24 on our tissue-agnostic MRD test, which is clinically validated for head & neck cancer and under development for additional cancer types. https://lnkd.in/gkXVyDkw
-
-
🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗜 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 Exploring the Bright Future of Double Immunochemotherapy in Metastatic Colorectal Cancer: Insights from the CHECKMATE 8WH Trial, Shared by Prof Eric Van Cutsem and Prof Van den Eynde. 👇 Watch all WND GI videos - link in the comments! #MediMix #GastricCancer #Immunotherapy #OncologyResearch
-
Prostate cancer is a common type of cancer in males, but it is highly treatable in the early stages. It begins in the prostate gland, which sits between the penis and the bladder. #dhf #DHF2024 #dovehavenfoundation #ProstateCancer #ProstateCancerPrevention #prostatecancerawareness
-
-
This Prostate Cancer Awareness Month, stay informed about the importance of early detection! Our latest blog covers everything you need to know about prostate cancer screening and how it can save lives. Get the facts and take control of your health. Read Part 1 here: https://hubs.la/Q02PJxTt0 #ProstateCancerAwarenessMonth #EarlyDetection
-
